<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="199">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919633</url>
  </required_header>
  <id_info>
    <org_study_id>4316001</org_study_id>
    <nct_id>NCT00919633</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C</brief_title>
  <acronym>COPE-HCV</acronym>
  <official_title>COPE-HCV: Continuous Interferon Delivery Via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Corporate Technologies and New Ventures</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Corporate Technologies and New Ventures</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon
      alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a
      safe and effective treatment for patients with chronic hepatitis C infection as compared to
      patients who receive standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients who are diagnosed with chronic hepatitis C genotype 1
      infection and who have received no previous interferon or other anti-HCV treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Viral Load: Incidence of Sustained Virologic Response (SVR)</measure>
    <time_frame>24 weeks after treatment is complete</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety/Tolerability</measure>
    <time_frame>Through study week 72</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid Virologic Response (RVR)</measure>
    <time_frame>Study Week 4</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Virologic Response (EVR)</measure>
    <time_frame>Study week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-of-treatment Response (EOT)</measure>
    <time_frame>Study week 48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>through Study Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>through Study Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Health, Depression Score, and Fatigue Level</measure>
    <time_frame>through Study Week 72</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Decay</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous subcutaneous infusion for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous subcutaneous infusion for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous subcutaneous infusion for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: peginterferon alfa-2b (1.5 μg/kg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subcutaneous weekly for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interferon alfa-2b</intervention_name>
    <description>subcutaneous continuous infusion at one of three doses for 48 weeks</description>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <other_name>INTRON® A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2b</intervention_name>
    <description>1.5 μg/kg subcutaneous weekly for 48 weeks</description>
    <arm_group_label>Group 4: peginterferon alfa-2b (1.5 μg/kg)</arm_group_label>
    <other_name>PEGINTRON™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin, USP</intervention_name>
    <description>All patients will receive oral ribavirin</description>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <arm_group_label>Group 4: peginterferon alfa-2b (1.5 μg/kg)</arm_group_label>
    <other_name>Rebetol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>external drug infusion pump</intervention_name>
    <description>pump delivery system for continuous subcutaneous infusion of interferon alfa-2b</description>
    <arm_group_label>Group 1: interferon alfa-2b (dose 1)</arm_group_label>
    <arm_group_label>Group 2: interferon alfa-2b (dose 2)</arm_group_label>
    <arm_group_label>Group 3: interferon alfa-2b (dose 3)</arm_group_label>
    <other_name>Medtronic MiniMed™ Paradigm® Insulin Pump Infusion System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed patient consent form

          -  Genotype 1 chronic HCV with detectable HCV RNA

          -  No previous treatment for HCV infection

          -  Hepatitis B and human immunodeficiency virus negative at screening visit

          -  Able and willing to follow contraception requirements

          -  Screening laboratory values, test, and physical exam within acceptable ranges

          -  Weight between 40 kg and 125 kg

          -  Proficiency in the use of the external pump infusion system

        Exclusion Criteria:

          -  Current or planned enrollment in another investigational device or drug study

          -  Anticipated inability to complete all clinic visits and comply with study procedures

          -  History of, or any current medical condition, which could impact the safety of the
             subject during the study

          -  Autoimmune hepatitis, suspected hepatocellular carcinoma, decompensated liver
             disease, or other known liver disease other than HCV

          -  Alcoholism or substance abuse with &lt;6 documented months of sobriety

          -  Known allergy or sensitivity to interferons or ribavirin

          -  Any other condition that, in the opinion of the Investigator, would make the subject
             unsuitable for enrollment or could interfere with the subject participating in and
             completing the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Muir, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Mische, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Ventures and New Therapies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html</url>
    <description>Viral cancers: Hepatitis C</description>
  </link>
  <link>
    <url>http://ctep.cancer.gov</url>
    <description>Common terminology criteria for adverse events, version 3.0</description>
  </link>
  <link>
    <url>http://www.ICMJE.org</url>
    <description>International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. Publication ethics: sponsorship, authorship and accountability.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 28, 2014</lastchanged_date>
  <firstreceived_date>June 10, 2009</firstreceived_date>
  <firstreceived_results_date>March 28, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>HCV</keyword>
  <keyword>genotype</keyword>
  <keyword>sustained virological response</keyword>
  <keyword>rapid virological response</keyword>
  <keyword>interferon</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
